午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Letermovir: First Global Approval.

Published:1 January 2018 DOI: 10.1007/s40265-017-0860-8 PMID: 29288370
Esther S Kim

Abstract

Letermovir (Prevymis?) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
LeterMovir 917389-32-3 C29H28F4N4O4 219 suppliers $15.00-$1680.00
Letermovir 710312-77-9 C34H47N11O9S2 7 suppliers Inquiry

Similar articles

IF:4.1

Capmatinib: First Approval.

ACS Chemical Neuroscience Sohita Dhillon,etc Published: 1 July 2020
IF:3.4

Sodium Thiosulfate: Pediatric First Approval.

Pediatric Drugs Sohita Dhillon,etc Published: 1 March 2023
IF:3.4

Letermovir for cytomegalovirus prophylaxis

Australian Prescriber Published: 24 April 2019